Healthcare Industry News:  MediciNova 


 News Release - September 8, 2008

MediciNova to Present At Merriman Curhan Ford's 5th Annual Investor Summit 2008

SAN DIEGO, Sept. 8, 2008 -- (Healthcare Sales & Marketing Network) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (NasdaqGM:MNOV ) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced that Dr. Michael Kalafer, Chief Medical Officer, and Shintaro Asako, Chief Financial Officer, of MediciNova will present a company overview at Merriman Curhan Ford's 5th Annual Investor Summit 2008 on Monday, September 15, 2008, at 11:15 a.m. Pacific time (2:15 p.m. Eastern time). The conference is being held at the Mark Hopkins InterContinental Hotel in San Francisco, California.

A live webcast of the presentation can be accessed through MediciNova's Investor Relations website at An archived version of the presentation will be available for approximately 60 days following the event.

About MediciNova

MediciNova, Inc. is a publicly-traded biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet need with a specific focus on the U.S. market. Through strategic alliances primarily with Japanese pharmaceutical companies, MediciNova holds rights to a diversified portfolio of clinical and preclinical product candidates, each of which MediciNova believes has a well-characterized and differentiated therapeutic profile, attractive commercial potential and patent assets having claims of commercially adequate scope. MediciNova's pipeline includes six clinical-stage compounds for the treatment of acute exacerbations of asthma, multiple sclerosis, asthma, interstitial cystitis, solid tumor cancers, Generalized Anxiety Disorder, preterm labor and urinary incontinence and two preclinical-stage compounds for the treatment of thrombotic disorders. MediciNova's current strategy is to focus its resources on the development and commercialization of two prioritized assets in its development pipeline: MN-221 for the treatment of acute exacerbations of asthma and MN-166 for the treatment of multiple sclerosis. MediciNova will seek to monetize its other product candidates at key value inflection points. For more information on MediciNova, Inc., please visit

Source: MediciNova

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.